The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects
The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Abstract
Rationale Increased activity of the hypothalamic-pituitary-adrenal (HPA) axis is an important aspect of the pathophysiology of major depression and schizophrenia. Despite the usefulness of atypical antipsychotics in the treatment of depression and their positive influence on cognitive functioning possibly related to their impact on cortisol, little is known about their effect on HPA axis function.Objective Therefore, this double-blind, placebo-controlled, randomized cross-over study investigated the influence of the atypical antipsychotics quetiapine and olanzapine in comparison with haloperidol and placebo on plasma adrenocorticotropic hormone (ACTH), cortisol, and prolactin levels. Eleven healthy male volunteers were studied during four sessions one week apart, orally receiving placebo, quetiapine (50 mg), olanzapine (5 mg), or haloperidol (3 mg). Blood samples were taken at hourly intervals from 0900 until 1700 hours. For ACTH, cortisol, and prolactin a significant effect of treatment condition (p < or = 0.005; p < or = 0.035; p < or = 0.0001, respectively) for area under the curve (AUC) was found. In comparison to placebo, quetiapine and olanzapine significantly reduced ACTH (p < or = 0.002; p < or = 0.05, respectively) and cortisol (p < or = 0.005; p < or = 0.03, respectively). No effect of haloperidol on AUC of ACTH or cortisol levels was observed. In comparison with placebo, haloperidol (p < or = 0.0001) and olanzapine (p < or = 0.0001) elevated AUC of prolactin plasma levels, whereas no significant effect was observed for quetiapine as a main effect of treatment condition. The atypical antipsychotics' strong influence on HPA-function with pronounced ACTH and cortisol lowering is possibly related to the atypicals' blockade of serotonergic receptors, but blockade of adrenergic or histaminergic receptors may play a role as well. The observed HPA-axis down-regulation may be clinically important for the atypicals' effects on depressive symptomatology and cognitive functioning.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“literature suggests that atypicals are associated with a greater reduction of cortisol than haloperidol”
From The HPA axis in bipolar disorder: Systematic review and meta-analysis (2016) · cites this paper as Cohrs et al. 2006
In the citing paper
“treatment with atypical antipsychotics, such as olanzapine, clozapine or risperidone, causes reduction in cortisol levels in patients with schizophrenia as well as in healthy controls”
From Abnormal cortisol levels during the day and cortisol awakening response in first-episode psychosis: The role of stress and of antipsychotic treatment (2010) · cites this paper as Cohrs et al., 2006
In the citing paper
“studies investigating typical antipsychotics like haloperidol, pimozide or sulpiride, reported that cortisol levels are unaffected by these drugs in healthy volunteers”
From Abnormal cortisol levels during the day and cortisol awakening response in first-episode psychosis: The role of stress and of antipsychotic treatment (2010) · cites this paper as Cohrs et al., 2006
Citations
Cites
The Corticosteroid Receptor Hypothesis of Depression
Holsboer, F. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00159-7 · Cited by 2,181
Tohen, M., Vieta, E., Calabrese, J., Ketter, T. A., Sachs, G., Bowden, C., Mitchell, P. B., Centorrino, F., Risser, R., Baker, R. W., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.11.1079 · Cited by 908 · cited 3×
“Recently, monotherapy with the atypical antipsychotics olanzapine (Tohen et al. 2003) and quetiapine (Calabrese et al.”
Binding of antipsychotic drugs to human brain receptors
Richelson, E., & Souder, T. (2000) · Life Sciences · doi:10.1016/s0024-3205(00)00911-5 · Cited by 607
Meltzer, H. Y. (1989) · Psychopharmacology · doi:10.1007/bf00442554 · Cited by 602
Association of depression with medical illness: Does cortisol play a role?
Brown, E. S., Varghese, F. P., & McEwen, B. S. (2004) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00473-6 · Cited by 578 · cited 4×
“Administration of corticoids impairs cognitive functioning (Brown et al. 2004; Belanoff et al. 2001) and a decrease of cortisol levels in patients suffering from Cushing’s disease (Mauri et al.”
InfluentialBilder, R. M., Goldman, R. S., Volavka, J., Czobor, P., Hoptman, M., Sheitman, B., Lindenmayer, J.-P., Citrome, L., McEvoy, J., Kunz, M., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.6.1018 · Cited by 538
Neurotransmitter regulation of anterior pituitary hormones.
Tuomisto, J., & Männistö, P. T. (1985) · PubMed · Cited by 531
A Novel Augmentation Strategy for Treating Resistant Major Depression
Shelton, R. C., Tollefson, G. D., Tohen, M., Stahl, S., Gannon, K. S., Jacobs, T. G., Buras, W. R., Bymaster, F. P., Zhang, W., Spencer, K. A., et al. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.1.131 · Cited by 504
Purdon, S. E. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.3.249 · Cited by 469
Kapur, S. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.6.553 · Cited by 396
Increase in Urinary Cortisol Excretion and Memory Declines: MacArthur Studies of Successful Aging1
Seeman, T. E., McEwen, B. S., Singer, B. H., Albert, M. S., & Rowe, J. W. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.8.4173 · Cited by 370
Belanoff, J. K., Gross, K., Yager, A., & Schatzberg, A. F. (2001) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(01)00018-8 · Cited by 310
The Effect of Neuroleptics on Serum Prolactin in Schizophrenic Patients
Meltzer, H. Y. (1976) · Archives of General Psychiatry · doi:10.1001/archpsyc.1976.01770030003001 · Cited by 294
Borison, R. L., Arvanitis, L. A., & Milier, B. G. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199604000-00008 · Cited by 268
Clinical use of quetiapine in disease states other than schizophrenia.
Dl, D., Laird, L. K., Zajecka, J., Bailey, L., Sussman, N., & Seabolt, J. L. (2002) · PubMed · Cited by 229
Sexual Dysfunction and Plasma Prolactin Levels in Neuroleptic-treated Schizophrenic Outpatients
GHADIRIAN, A. M., CHOUINARD, G., & ANNABLE, L. (1982) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198208000-00004 · Cited by 224
Treatment of Depression With Antiglucocorticoid Drugs
Wolkowitz, O. M., & Reus, V. I. (1999) · Psychosomatic Medicine · doi:10.1097/00006842-199909000-00011 · Cited by 209
Volavka, J., Czobor, P., Cooper, T. B., Sheitman, B., Lindenmayer, J.-P., Citrome, L., McEvoy, J. P., & Lieberman, J. A. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0109 · Cited by 201
Prolactin Responses to Neuroleptics in Normal and Schizophrenic Subjects
Gruen, P. H. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770250110011 · Cited by 193
Cognitive functioning, cortisol release, and symptom severity in patients with schizophrenia
Walder, D. J., Walker, E. F., & Lewine, R. J. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01052-0 · Cited by 192
Elevation of Prolactin Levels by Atypical Antipsychotics
Turrone, P., Kapur, S., Seeman, M. V., & Flint, A. J. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.1.133 · Cited by 190
Does cognitive function improve with quetiapine in comparison to haloperidol?
Velligan, D. I., Newcomer, J., Pultz, J., Csernansky, J., Hoff, A. L., Mahurin, R., & Miller, A. L. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00268-7 · Cited by 183
Wieck, A., & Haddad, P. M. (2003) · British Journal of Psychiatry · doi:10.1192/bjp.182.3.199 · Cited by 167
Dosing the antipsychotic medication olanzapine.
Nemeroff, C. B. (1997) · PubMed · Cited by 153
Memory impairment in Cushing's disease
Mauri, M., Sinforiani, E., Bono, G., Vignati, F., Berselli, M. E., Attanasio, R., & Nappi, G. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1993.tb04075.x · Cited by 151
Management of the Negative Symptoms of Schizophrenia: New Treatment Options
M??ller, H.-J. (2003) · CNS Drugs · doi:10.2165/00023210-200317110-00003 · Cited by 141
Shirayama, Y., Hashimoto, K., Suzuki, Y., & Higuchi, T. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00367-x · Cited by 137
Depression in Schizophrenia: Are Neuroleptics, Akinesia, or Anhedonia Involved?
Harrow, M., Yonan, C. A., Sands, J. R., & Marengo, J. (1994) · Schizophrenia Bulletin · doi:10.1093/schbul/20.2.327 · Cited by 131
Antipsychotics: impact on prolactin levels
Goodnick, P. J., Santana, O., & Rodriguez, L. (2002) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.3.10.1381 · Cited by 121
The Effect of Clozapine on Plasma Norepinephrine: Relationship to Clinical Efficacy
Breier, A. F., Buchanan, R. W., Waltrip, R. W., Listwak, S. J., Holmes, C. S., & Goldstein, D. S. (1994) · Neuropsychopharmacology · doi:10.1038/npp.1994.1 · Cited by 121
Human prolactin responses to neuroleptic drugs correlate with antischizophrenic potency
LANGER, G., Sachar, E. J., GRUEN, P. H., & Halpern, F. S. (1977) · Nature · doi:10.1038/266639a0 · Cited by 116
Altamura, A. C., Boin, F., & Maes, M. H. J. (1999) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(99)00017-6 · Cited by 113
Meltzer, H. Y. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1088-0 · Cited by 109
Seibyl, J. P., Krystal, J. H., Price, L. H., Woods, S. W., D'Amico, C., Heninger, G. R., & Charney, D. S. (1991) · Psychiatry Research · doi:10.1016/0165-1781(91)90013-f · Cited by 104
Adrenergic control of the secretion of anterior pituitary hormones
Al‐Damluji, S. (1993) · Baillière s Clinical Endocrinology and Metabolism · doi:10.1016/s0950-351x(05)80180-6 · Cited by 90
Contesse, V., Lefebvre, H., Lenglet, S., Kuhn, J.-M., Delarue, C., & Vaudry, H. (2000) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-78-12-967 · Cited by 83
Laakmann, G., Schoen, H., Zygan, K., Weiss, A., Wittmann, M., & Meissner, R. (1986) · Psychoneuroendocrinology · doi:10.1016/0306-4530(86)90007-7 · Cited by 79
Laakmann, G., Wittmann, M., Gugath, M., Mueller, O. A., Treusch, J., Wahlster, U., & Stalla, G. K. (1984) · Psychopharmacology · doi:10.1007/bf00432027 · Cited by 78
Wetzel, H., Wiesner, J., Hiemke, C., & Benkert, O. (1994) · Journal of Psychiatric Research · doi:10.1016/0022-3956(94)90004-3 · Cited by 66
Schüle, C., Baghai, T. C., Zwanzger, P., Ella, R., Eser, D., Padberg, F., Möller, H., & Rupprecht, R. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1356-z · Cited by 65
ENDOCRINE EFFECTS OF PIMOZIDE, A SPECIFIC DOPAMINERGIC BLOCKER
COLLU, R., Jéquier, J.-C., LEBOEUF, G., Letarte, J., & DUCHARME, J. R. (1975) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-41-5-981 · Cited by 65
Effects of mirtazapine on growth hormone, prolactin, and cortisol secretion in healthy male subjects
Laakmann, G., Schüle, C., Baghai, T. C., & Waldvogel, E. (1999) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(99)00029-3 · Cited by 55
Markianos, M., Hatzimanolis, J., & Lykouras, L. (1999) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(99)00040-1 · Cited by 53
American Psychiatric Association -- 157th Annual Meeting.
Susman, E. (2004) · PubMed · Cited by 52
Plasma prolactin in schizophrenia subjects treated with Seroquel (ICI 204,636).
Hamner, M. B., Arvanitis, L. A., Miller, B. G., Link, C. G. G., & Hong, W. W. (1996) · PubMed · Cited by 51
Nürnberger, J. I., Simmons-Alling, S., Kessler, L. R., Jimerson, S. S., Schreiber, J. G., Hollander, E., Tamminga, C. A., Nadi, N. S., Goldstein, D. S., & Gershon, E. S. (1984) · Psychopharmacology · doi:10.1007/bf00427446 · Cited by 51
Quetiapine reduces nocturnal urinary cortisol excretion in healthy subjects
Cohrs, S., Pohlmann, K., Guan, Z., Jordan, W., Meier, A., Huether, G., R�ther, E., & Rodenbeck, A. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1766-6 · Cited by 47
Self-citationWetzel, H., Szegedi, A., Hain, C., Wiesner, J., Schlegel, S., & Benkert, O. (1995) · Psychopharmacology · doi:10.1007/bf02246165 · Cited by 46
Psychoneuroendocrinology: The Scientific Basis of Clinical Practice
Peiris, A. N. (2004) · Southern Medical Journal · doi:10.1097/00007611-200401000-00036 · Cited by 46
Baptista, T., Molina, M., Martinez, J., de Quijada, M., de Cuesta, I., Acosta, A., Páez, X., Martinez, J., & Hernández, L. (1997) · Pharmacopsychiatry · doi:10.1055/s-2007-979503 · Cited by 44
Selective neuroendocrine effects of low-dose haloperidol in normal adult men
Rubín, R. T., Poland, R. E., O'Connor, D., Gouin, P. R., & Tower, B. B. (1976) · Psychopharmacology · doi:10.1007/bf00735811 · Cited by 44
Laakmann, G., Wittmann, M., Schoen, H., Zygan, K., Weiss, A., Meissner, R., Mueller, O. A., & Stalla, G. K. (1986) · Psychoneuroendocrinology · doi:10.1016/0306-4530(86)90008-9 · Cited by 42
Effect of the serotonin antagonists ritanserin and ketanserin in Cushing’s disease
Sonino, N., Fava, G. A., Fallo, F., Franceschetto, A., Belluardo, P., & Boscaro, M. (2000) · Pituitary · doi:10.1023/a:1009986822146 · Cited by 41 · cited 2×
“…(mCPP), on positive symptoms and plasma cortisol levels in schizophrenic patients (Abi Saab et al. 2002), and a reduction of cortisol levels after the administration of ritanserin has also been found in patients with Cushing’s disease (Sonino et al. 2000) and healthy subjects (Seibyl et al. 1991).”
Scheepers, F. E., Gispen de Wied, C. C., & Kahn, R. S. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200112000-00006 · Cited by 40
WILCOX, C. S., AMINOFF, M. J., MILLAR, J. G. B., KEENAN, J., & KREMER, M. (1975) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1975.tb01526.x · Cited by 38
von Bahr, C., Wiesel, F., Movin, G., Eneroth, P. H. E., Jansson, P., Nilsson, L., & Ogenstad, S. (1991) · Psychopharmacology · doi:10.1007/bf02244242 · Cited by 38
Baptista, T., Alastre, T., Contreras, Q., Martinez, J., de Baptista, E., Páez, X., & Hernández, L. (1997) · Pharmacopsychiatry · doi:10.1055/s-2007-979502 · Cited by 37
Kahn, R. S., Siever, L. J., Davidson, M., Greenwald, C., & Moore, C. (1993) · Psychopharmacology · doi:10.1007/bf02245012 · Cited by 33
Central dopamine receptors mediating pergolide-induced elevation of serum corticosterone in rats
Fuller, R. W., & Snoddy, H. D. (1984) · Neuropharmacology · doi:10.1016/0028-3908(84)90078-9 · Cited by 29
Haloperidol increases plasma beta endorphin-like immunoreactivity and cortisol in normal human males
Murburg, M. M., Paly, D., Wilkinson, C. W., Veith, R. C., Malas, K. L., & Dorsa, D. M. (1986) · Life Sciences · doi:10.1016/0024-3205(86)90656-9 · Cited by 29
Koning, P. D., & de Vries, M. H. (1995) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1995.tb04403.x · Cited by 29
Abi‐Saab, W., Seibyl, J. P., D’Souza, C., Karper, L. P., Gueorgueva, R., Abi‐Dargham, A., Wong, M., Rajhans, S., Erdos, J., Heninger, G. R., et al. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1057-7 · Cited by 27
Neurochemical variables in schizophrenic patients during switching from neuroleptics to clozapine
Hatzimanolis, J., Lykouras, L., Markianos, M., & Oulis, P. (1998) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(98)00064-5 · Cited by 26
Scientific Basis of Clinical Practice
MacDonald, R. (1971) · BMJ · doi:10.1136/bmj.4.5788.685-c · Cited by 24
Marco, E. J., Wolkowitz, O. M., Vinogradov, S., Poole, J. H., Lichtmacher, J. E., & Reus, V. I. (2002) · The World Journal of Biological Psychiatry · doi:10.3109/15622970209150617 · Cited by 19
EFFECT OF MECLASTINE, A SELECTIVE H1 RECEPTOR ANTAGONIST, UPON ACTH RELEASE
Allolio, B., DEUSS, U., KAULEN, D., & Winkelmann, W. (1983) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1983.tb02986.x · Cited by 17
Prolactin Elevation With Quetiapine
ALEXIADIS, M., Whitehorn, D., Woodley, H. G., & Kopala, L. C. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.9.1608 · Cited by 17
Suppression of HPA-axis activity by haloperidol after experimentally induced heat stress
Hennig, J., Rzepka, U., Mai, B., & Netter, P. (1995) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(95)00105-5 · Cited by 16
Murburg, M. M., Wilkinson, C. W., Raskind, M. A., Veith, R. C., & Dorsa, D. M. (1993) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.77.4.8408451 · Cited by 15
Sulpiride-induced hyperprolactinemia and impotence in male psychiatric outpatients
Weizman, A., MAOZ, B., Treves, I., Asher, I., & Ben‐David, M. (1985) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(85)90082-x · Cited by 14
Ježová, D., Klimeś, I., Jur̀čovičová, J., & Vigas, M. (1979) · PubMed · Cited by 13
Allolio, B., Schulte, H. M., DEUSS, U., & Winkelmann, W. (1987) · PubMed · Cited by 9
Barbieri, C., Parodi, M., Bruno, S., Bertassi, F., Benaglia, D., Moser, P. C., Meroni, R., & Dubini, A. (1984) · European Journal of Clinical Pharmacology · doi:10.1007/bf00546704 · Cited by 9
Hornig, M., & Amsterdam, J. D. (2003) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9798894550442.lg05 · Cited by 2
Cited by
Cortisol stress reactivity across psychiatric disorders: a systematic review and meta-analysis
Zorn, J. V., Schür, R. R., Boks, M. P., Kahn, R. S., Joëls, M., & Vinkers, C. H. (2017) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2016.11.036 · Cited by 697
Stress and the hypothalamic pituitary adrenal axis in the developmental course of schizophrenia
Walker, E., Mittal, V., & Tessner, K. (2008) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.4.022007.141248 · Cited by 615
Sleep Disturbances in Patients with Schizophrenia: Impact and Effect of Antipsychotics
Cohrs, S. (2008) · CNS Drugs · doi:10.2165/00023210-200822110-00004 · Cited by 433
Self-citationThe HPA axis in bipolar disorder: Systematic review and meta-analysis
Belvederi Murri, M., Prestia, D., Mondelli, V., Pariante, C., Patti, S., Olivieri, B., Arzani, C., Masotti, M., Respino, M., Antonioli, M., et al. (2016) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2015.10.014 · Cited by 391
Pruessner, M., Cullen, A. E., Aas, M., & Walker, E. F. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.12.013 · Cited by 315
“The most common effect is a dampening of HPA activity documented with atypical antipsychotics (Zhang et al., 2005, Cohrs et al., 2006, Venkatasubramanian et al., 2010) and some antidepressants (Manthey et al., 2011).”
Background
Metadata
- Authors
- Cohrs, S., Röher, C., Jordan, W., Meier, A., Huether, G., Wuttke, W., Rüther, E., & Rodenbeck, A.
- Affiliations
- University of Göttingen (DE)
- Corresponding author
- Cohrs, Stefan
- ORCID
- Meier, Andreas
- Venue
- Psychopharmacology
- Published
- 2006-01-24
- Volume
- 185
- Issue
- 1
- Pages
- 11-18
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W2071272920
- Cited by
- 141
- References
- 74
- Citations by year
- 2025: 2 · 2024: 2 · 2023: 3 · 2022: 7 · 2021: 5 · 2020: 12 · 2019: 6 · 2018: 7 · 2017: 5 · 2016: 10 · 2015: 5 · 2014: 12 · 2013: 11 · 2012: 4
- FWCI
- 5.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- GRO (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- atypical antipsychotics, olanzapine, quetiapine, haloperidol, hypothalamic-pituitary-adrenal axis, ACTH secretion, cortisol, prolactin, depression, schizophrenia, cognitive function
- MeSH terms
- Quetiapine Fumarate, Olanzapine, Adrenocorticotropic Hormone, Adult, Benzodiazepines, Dibenzothiazepines, Double-Blind Method, Haloperidol, Humans, Hydrocortisone, Hypothalamo-Hypophyseal System, Male, Pituitary-Adrenal System, Prolactin, Antipsychotic Agents, Cross-Over Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.